TOMSK, RUSSIA / RankWire.AI / – Russian scientists have developed and tested a bioactive coating aimed at enhancing the integration of titanium orthopaedic implants with bone tissue. This innovative material incorporates calcium phosphate derived from hydroxyapatite and includes nitrogen compounds associated with nitric oxide production. Laboratory evaluations demonstrated that human mesenchymal stem cells exhibited significantly higher survival rates on coated surfaces compared to uncoated titanium. The research team analyzed the coating’s structure, chemistry, mechanical properties, and biological responses. Their peer-reviewed results appeared in Applied Surface Science in 2026.
At Tomsk Polytechnic University, scientists produced these experimental coatings through reactive magnetron sputtering of a hydroxyapatite target within a vacuum chamber. They manipulated the nitrogen and argon gas mixture during the process to observe how each variation affected the resulting surface. The study tested five different conditions, ranging from pure nitrogen to pure argon. The team measured parameters such as coating thickness, surface morphology, hardness, wettability, and chemical composition. Additionally, they conducted laboratory experiments to determine how living human cells responded to the modified titanium surfaces.
Results indicated that the argon content influenced several physical aspects of the coatings. Surfaces created in pure argon were found to be denser and harder than those deposited in pure nitrogen. The thickness of the coatings also increased with higher proportions of argon. Chemical analyses revealed nitrogen-carbon and nitrogen-oxygen bonds on the modified surfaces. The researchers then compared the growth of human mesenchymal stem cells on coated titanium versus uncoated titanium, assessing cell viability and markers linked to osteogenic differentiation.
Enhanced Cell Survival Demonstrated in Coating Tests
Experimental results showed that coated surfaces supported significantly better cell survival than uncoated titanium. After a seven-day period, coatings with higher nitrogen content were also associated with a reduction in activity of specific genes related to early bone-cell differentiation. Despite this, the cells retained their capacity for bone formation. These biological assessments were carried out under controlled laboratory conditions using human mesenchymal stem cells, with no clinical trials or patient-based testing conducted as part of this study.
The biomedical evaluation was performed by researchers from Immanuel Kant Baltic Federal University and Siberian State Medical University. The broader research team also included specialists from Saint Petersburg State University. Funding was provided through Russia’s national science program. The primary focus was on identifying gas mixtures that could produce optimal combinations of physical, chemical, and biological coating properties. Since hydroxyapatite’s calcium phosphate composition closely resembles mineral components found in human bone, it is already used in some implant coatings.
Further Testing Needed to Confirm Practical Applications
The research team has outlined plans for additional testing beyond the initial seven-day cell experiments. Future studies will explore stem cell responses over periods of 10 to 28 days, as well as investigate coating dissolution rates and nitric oxide release in living tissues. These investigations are not part of the current laboratory results, which focus on coated titanium substrates, material properties, and in vitro cell responses rather than clinical outcomes in orthopaedic patients.
The study offers comprehensive laboratory data showing how varying ratios of nitrogen and argon influence calcium phosphate coatings on titanium surfaces. The researchers documented differences in coating thickness, density, hardness, chemical bonding, and cellular responses based on the different gas mixtures. Results also indicated that coated samples supported higher survival rates of stem cells compared to bare titanium under the tested conditions. Nonetheless, the findings are at the preclinical stage, and the experiments do not establish safety or effectiveness for use in human patients. Additional biological testing will be necessary to evaluate properties not addressed in this initial work.